# Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

> **NCT00287547** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 144 (—)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** CTLA4Ig / Abatacept

## Key facts

- **NCT ID:** NCT00287547
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-03
- **Primary completion:** 1998-01
- **Final completion:** 1998-01
- **Target enrollment:** 144 (—)
- **Last updated:** 2011-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287547, "Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00287547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*